Entrevestor: Densitas Partners with U.S. Beta User

Halifax-based breast imaging analytics company Densitas has announced a collaboration with TeleMammography Specialists of Decatur, Georgia, that will improve the quality of breast screening offered to more than 60,000 women annually.
TeleMammography Specialists is an international teleradiology services provider and will be the first U.S. beta user for the new densitasquality solution, the company said in a statement. The product will improve the communications and information sharing needed to meet FDA guidelines.
TeleMammography Specialists also plan to implement the recently released densitasdensity automated breast density assessment software.
“Our goal is to provide tools that reduce the documentation, process and communication burdens of meeting EQUIP (FDA) guidelines and enables sustainable delivery of quality assurance across the mammography enterprise,” Mohamed Abdolell, CEO of Densitas, said in the statement.

See full article here

Densitas Enters Platform Partnership with Blackford

PRNewswire/ – Densitas, Inc., a breast imaging analytics innovator based in Halifax, Nova Scotia, today announced the signing of a new Alliance Partner Agreement with Blackford. This agreement gives Blackford the right to promote, market, sell, distribute, and license densitasdensity™ directly via integration with the Blackford Platform™. Work will now commence to integrate densitasdensity™ with the Blackford Platform. “The platform approach will help us bring new products to market more quickly, support our scaling activities, and simplify integration for our customers” says Mohamed Abdolell, CEO of Densitas. “We expect the Blackford Platform to reduce our time to market and shorten our sales cycle as we will be incorporated as an extension of the Blackford Platform infrastructure.” The densitasdensity™ software provides an automated mechanism for quantifying and recording percent breast tissue density, and making it readily available to the radiologist. Beyond speeding and simplifying the process of quantifying breast density, densitasdensity™ standardizes the density measurement which enables uniform application of risk-based stratification of screen eligible women aimed at ensuring those who need more aggressive follow-up receive it, while those who do not need aggressive follow-up do not receive unnecessary imaging. Densitas software is unique in that it assesses breast density using the routinely archived processed DICOM images that radiologists normally review, and therefore supports prospective and retrospective breast density measurement for clinical care and for research. Blackford CEO, Ben Panter said this of the alliance: “We are delighted to add densitasdensity™ to the curated marketplace of applications available through Blackford Platform. We look forward to working with Densitas to provide our customers and channel partners multiple imaging applications that can be easily deployed and maintained.” densitasdensity™ will be demonstrated at the upcoming Radiological Society of North America (RSNA) 2018 annual meeting in Chicago. Densitas personnel will be available to discuss the benefits and capabilities of density in Booth #3274 – South Hall at RSNA and in the machine learning pavilion, Kiosk #7367W – North Hall. To learn more about Blackford Platform applications including densitasdensity™, book a demo at RSNA or visit Blackford at Booth #7364. About Densitas: Densitas’ vision is to move the needle in breast cancer screening through tailored patient management for sustainable healthcare service delivery and improved outcomes. Densitas develops advanced breast imaging analytics technologies powered by machine learning with the goal to deliver on-demand actionable insights that improve the quality of breast health management. Our products tackle the key challenges facing women’s imaging today, including mammography quality, workflow efficiencies, compliance with national guidelines, and delivery of appropriate care at sustainable costs. Learn more at www.densitas.health and in our virtual press kit. About Blackford Blackford provide a single platform to quickly access and manage a curated marketplace of regulatory approved medical image analysis applications and AI algorithms that add clinical value. Easily integrated into existing workflows, the platform provides actionable information that allows healthcare providers to use imaging information smartly and reduce the cost of care, while improving diagnostic confidence and patient outcomes. Founded in 2010, and with operations in the United Kingdom and the United States, Blackford Analysis is backed by TRI Cap, Old College Capital, and Archangel Investors, one of the UK’s leading business angel syndicates. For more information, visit www.blackfordanalysis.com Contact Information: Media Contact Densitas: Alex Morris alex@densitas.health 647-470-4363 Media Contact Blackford: Greg Kingston greg@blackfordanalysis.com +44 131 6688 411]]>

NEWS RELEASE: Densitas and Leeds Teaching Hospitals sign partnership to bring innovative, personalized breast screening technologies into their routine clinical workflow

Will enable mammography quality improvement and population level stratified breast screening.

HALIFAX, NS., Canada, July 24, 2018 /PRNewswire/ ‑ Densitas, Inc., a breast imaging analytics innovator based in Halifax, Nova Scotia, announces a recently formalized partnership with the Leeds Teaching Hospitals NHS Trust in the UK. The partnership seeks to introduce innovative personalized breast screening technologies, including our DENSITAS|density™ and DENSITAS|quality™ products, into routine clinical workflow. The goal is to ultimately enable population level stratified breast screening and mammography quality improvement and stimulate research in the area of breast health. “Our partnership  with Leeds Teaching Hospitals, NHS Trust is the first of its kind in the UK and represents an alignment of vision that is intended to improve appropriateness of care in breast cancer screening through innovation in technology and service delivery,” says Mohamed Abdolell, CEO of Densitas. “We are excited to collaborate with Dr. Nisha Sharma, Director of Breast Screening, and her team at Leeds Teaching Hospital’s NHS Trust breast screening program to introduce our machine learning powered breast imaging analytics platform into a clinical care setting.” Breast tissue density is a confirmed independent risk factor for breast cancer in women. The current standard of care in the UK National Health Service is subjective, visual assessment of breast tissue density by the radiologist, if it is performed at all. The Densitas|density™ software provides an automated mechanism for quantifying and recording breast density, and making it readily available to the radiologist, along with the digital mammograms. This will allow the Leeds team to assess breast density for every woman who has a screening mammogram performed. Beyond speeding and simplifying the process of quantifying breast density, Densitas|density™ standardizes the density measurement and enables stratification of screen eligible women to ensure those who need more aggressive follow-up receive it, while those who do not need aggressive follow-up do not receive unnecessary imaging. Densitas software is unique in that it assesses breast density using the routinely archived processed DICOM images that radiologists normally review, and therefore supports prospective and retrospective breast density measurement for clinical care and for research. Dr Sharma said: “This is a really exciting development for us because it has the potential to make a real difference to the quality of our screening program and ultimately to the health outcomes of women in Leeds. I’m very pleased that the Leeds Breast Screening unit and research team have the opportunity to collaborate with Densitas. This is the foundation for future developments that will improve breast care, so it’s excellent news for women.” About Densitas: Densitas, Inc. develops advanced breast imaging analytics technologies powered by machine learning. Our goal is to deliver actionable insights at the point-of-care that improve the quality of breast health management. Our products address the key challenges facing women’s imaging today, including mammography quality, workflow efficiencies, compliance with national guidelines, and delivery of appropriate care at sustainable costs. Learn more at www.densitas.health
For further information: Alex Morris, 647-470-4363
]]>

DENSITAS: Densitas Receives 510(k) Clearance for Breast Density Software

See original story here  Breast imaging analytics innovator Densitas Inc. announced today that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) to market its machine learning breast density assessment software. The software empowers radiologists with standardized, personalized and automated density reports to optimize women’s breast health and follow-up care decisions.“Receiving 510(k) clearance marks a significant milestone in our company’s growth as we expand our global reach into the U.S. market with our flagship product,” said Mohamed Abdolell, CEO of Densitas. We are delighted to be entering the largest medical device market in the world, especially as 31 states have passed mandatory breast density notification laws.” Breast density has been shown to be strongly associated with cancer risk. Densitas has the distinct advantage of facilitating breast density assessments of routinely stored standard processed images and their priors because the technology processes the same standard digital mammograms that radiologists view.  This provides a practical solution for integrating breast density into risk-based models in population-based screening.The software is cleared for clinical use in the U.S., Europe, Canada and Australia, and is the first of several follow-on products. The software is being showcased at the European Congress of Radiology (ECR 2018), booth 114 at the Austria Center Vienna.About Densitas Densitas develops advanced imaging analytics technologies powered by machine learning that deliver actionable insights at point-of-care for personalized breast health. Our products address the key challenges facing breast imaging today, including mammography quality, workflow efficiencies, compliance with national guidelines and standards, and delivery of appropriate care at sustainable costs. For more information, visit www.densitas.health]]>

Densitas: DENSITAS SOFTWARE CLEARED FOR SALE IN AUSTRALIA

See original story here Densitas Inc. announced today that it has received regulatory clearance for its automated breast density software, DM-Density. DM-Density has received regulatory clearance from the Australian Therapeutic Goods Administration (TGA) and will be available through the EnvoyAI Platform. Australia has approximately 12 million women and 1.7 million are screened for breast cancer using mammography every two years. Breast cancer is the most commonly diagnosed cancer in Australian women aged 50-74, with 300 new cases for every 100,000 women. Breast cancer is the second most common cause of cancer mortality in Australian women aged 50-74, with approximately 45 deaths per 100,000 women. The Australian Government has increased its commitment to the early detection of breast cancer by recently expanding the BreastScreen Australia target age to include women 70-74. Phillip Cahill, Director of Diagnostic Imaging Australia, EnvoyAI’s Australian distributor, will launch DM-Density into the Australian market. “We are pleased to be able to offer Densitas’ software in Australia, as it fills a need for radiologists looking for a reliable and standardized breast density solution. Densitas automatically reads and categorizes each mammogram, determining a patient’s breast density category, in a matter of a few seconds. The deployment of the Densitas algorithm on the Envoy AI platform is a natural fit that radiologists will find to be seamless,” said Mr. Cahill. “We are excited that doctors and patients in Australia can now benefit from our advanced machine learning algorithms to assess breast density,” said Mohamed Abdolell, CEO of Densitas. “Our entry into the Australian market marks further expansion of our technology globally.” About Densitas (www.densitas.health) Densitas develops advanced imaging analytics technologies powered by machine learning that deliver actionable insights at point-of-care for high quality personalized breast health.  Our products address the key challenges facing breast imaging today, including mammography quality, workflow efficiencies, compliance with national guidelines and standards, and delivery of appropriate care at sustainable costs. About EnvoyAI (www.envoyai.com) EnvoyAI facilitates the streamlined distribution and hospital implementation of trained machine learning algorithms via a vendor neutral distribution platform. EnvoyAI provides a developer platform, integrations, and an open API for algorithm developers, technology partners, and end users. EnvoyAI also works with distribution partners to make algorithms on the platform available to a wide footprint of hospitals and, ultimately, to physicians. ContactAlex Morris]]>